CriticalOxazolidinone antibiotic×Opioid analgesic with dual mechanism
Updated · Methodology
Mechanism
Tapentadol is an opioid analgesic: it stimulates mu-opioid receptors and also inhibits noradrenaline reuptake (tapentadol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Besides its antibacterial action, linezolid is a reversible, non-selective inhibitor of the enzyme monoamine oxidase (MAO), so it belongs to the MAO inhibitors (linezolid SmPC, AEMPS, section 4.5). According to the Spanish tapentadol SmPC, MAO inhibitors can raise synaptic noradrenaline concentrations even further, which may lead to cardiovascular adverse reactions such as hypertensive crisis (tapentadol SmPC, AEMPS, section 4.5). According to the US tapentadol label, linezolid impairs the metabolism of serotonin, and MAO inhibitor interactions with opioids may present as serotonin syndrome or opioid toxicity (tapentadol label, US Food and Drug Administration, FDA, sections 5.7 and 7). The linezolid SmPC reports cases of serotonin syndrome when linezolid was combined with serotonergic agents, opioids included (linezolid SmPC, AEMPS, sections 4.4 and 4.5).
Symptoms
The documents do not say how this particular combination presents: they contraindicate it pre-emptively. Possible outcomes are a hypertensive crisis due to higher noradrenaline concentrations (tapentadol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5), serotonin syndrome, or opioid toxicity with respiratory depression and coma (tapentadol label, US Food and Drug Administration, FDA, section 7). According to the Spanish tapentadol SmPC, serotonin syndrome presents with spontaneous or inducible clonus, ocular clonus included, with agitation or sweating, tremor and overactive reflexes, increased muscle tone and a body temperature above 38 °C (tapentadol SmPC, AEMPS, section 4.5). The linezolid SmPC lists cognitive dysfunction, high fever, overactive reflexes and poor coordination (linezolid SmPC, AEMPS, section 4.4). Symptoms usually start within several hours to a few days of combined use, but may start later, and the syndrome can be fatal (FDA tapentadol label, section 5.7).
Management
The combination is contraindicated. The US tapentadol label prohibits taking tapentadol with monoamine oxidase (MAO) inhibitors or within 14 days of stopping them, and names linezolid among the examples (tapentadol label, US Food and Drug Administration, FDA, sections 4 and 7). Linezolid is an MAO inhibitor according to its own documents (linezolid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5; linezolid FDA label, section 7.1). The Spanish tapentadol SmPC is milder: it advises avoiding tapentadol in patients who take MAO inhibitors or have taken them in the last 14 days (tapentadol SmPC, AEMPS, section 4.5). The Spanish linezolid SmPC contraindicates linezolid with serotonergic agents, opioids included, unless the combination is absolutely necessary (linezolid SmPC, AEMPS, section 4.4). Start tapentadol no earlier than 14 days after stopping linezolid (tapentadol SmPC, AEMPS, section 4.5; FDA tapentadol label, sections 4 and 7). Do not start MAO inhibitors, linezolid included, while the patient is taking tapentadol (FDA tapentadol label, section 17). If an opioid is needed urgently, the US tapentadol label advises treating pain with other opioids, such as oxycodone, hydrocodone, oxymorphone or buprenorphine. Start with test doses, titrate small doses frequently and closely monitor blood pressure and signs of central nervous system and respiratory depression (FDA tapentadol label, section 7). If the combination cannot be avoided, watch the patient closely for signs of serotonin syndrome; if they appear, consider stopping one or both drugs (linezolid SmPC, AEMPS, section 4.4). If serotonin syndrome is suspected, stop tapentadol (FDA tapentadol label, section 5.7) and start supportive treatment (linezolid FDA label, section 5.3).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Zyvox (linezolid) prescribing information (2026)– FDA, DailyMed setid 6e70e63b-bfd5-478d-a8ee-8ba22c9efabd (Pharmacia & Upjohn), version 72, revised 06/2026, sections 4.2, 5.3, 5.9, 7.1, 7.2 and 12.3
- AEMPS: Ficha técnica: Linezolid, Zyvoxid 600 mg (nº registro 64109) (2026)– AEMPS, CIMA, nº registro 64109 (Zyvoxid 600 mg comprimidos recubiertos con película), revisión 05/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Tapentadol, Palexia retard 100 mg (nº registro 73244), sección 4.5 (2026)– AEMPS, CIMA, nº registro 73244 (Palexia retard 100 mg comprimidos de liberación prolongada, Grünenthal Pharma), revisión 01/2026, secciones 4.4, 4.5 y 5.1
- FDA: Nucynta (tapentadol) tablets prescribing information (2025)– FDA, DailyMed setid 80938c30-9fe3-4c7d-9d9c-5476638cfb2d (Collegium Pharmaceutical), versión 7, vigente desde 30.12.2025, secciones 4, 5.7, 7 y 17